Tracers / [225Ac]Ac-DOTAZOL
[225Ac]Ac-DOTAZOL
Also written as [Ac-225]Ac-DOTAZOL; DOTAZOL
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical
- Syntheses indexed
- 1
What it is
- Compound class
- DOTA-conjugated bisphosphonate (zoledronic acid derivative)
- Target / mechanism
- Bone mineral (hydroxyapatite) targeting via bisphosphonate moiety PMID 29564390
- Clinical application
- Bone metastases (palliative alpha-therapy for painful skeletal metastases) PMID 29866026
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| — | — | none | ≥98 % | — | DOTAZOL | 29866026 2018 Curr Radiopharm DOTAZOL was labelled with 225Ac and injected without further purification into the tail vein — Radiolabelling of DOTAZOL with 225Ac at 98 °C provided radiochemical yields ≥98 % within 30 minutes. |
Need this precursor?We can point you to suppliers for [225Ac]Ac-DOTAZOL, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.